CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 12 enrolled
Drug / intervention
UroLiftdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04271020
NCT04271020N/ACompleted
CompareCT.gov

Urodynamic Feasibility Study (UDS)

NeoTract, Inc.·interventional·Posted Feb 17, 2020·Updated Jun 11, 2020

In Brief

A clinical study evaluating UroLift for Benign Prostatic Hyperplasia. Completed, enrolled 12 participants across 1 site.

Detailed Summary

UDS evaluates the impact of Prostatic Urethral Lift (PUL) as measured by pressure flow, urodynamic testing (UDS) and an optional UroCuff Testing, an alternative urodynamic test. In addition, standard BPH measures such as symptoms, qualify of life, uroflowmetry, and post void residual will be evaluated at screening and at the follow-up visits.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBenign Prostatic Hyperplasia
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedFeb 17, 2020
Enrollment StartOct 25, 2018
Primary CompletionApr 22, 2019
Study CompletionNov 27, 2019
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 6.4 years ago

Interventions

UroLiftdevice

The UroLift System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH). During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.